CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 444 filers reported holding CRISPR THERAPEUTICS AG in Q1 2022. The put-call ratio across all filers is 0.99 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $400,334 | +23.2% | 7,131 | -0.7% | 0.01% | +8.3% |
| Q1 2023 | $324,887 | +11.2% | 7,183 | -0.1% | 0.01% | 0.0% |
| Q4 2022 | $292,233 | -44.1% | 7,189 | -10.1% | 0.01% | -47.8% |
| Q3 2022 | $523,000 | -17.6% | 7,998 | -8.5% | 0.02% | -14.8% |
| Q2 2022 | $635,000 | +31.7% | 8,738 | +12.7% | 0.03% | +42.1% |
| Q1 2022 | $482,000 | -11.2% | 7,756 | -0.2% | 0.02% | -5.0% |
| Q4 2021 | $543,000 | +31.2% | 7,773 | +92.4% | 0.02% | +11.1% |
| Q3 2021 | $414,000 | +27.4% | 4,041 | +79.4% | 0.02% | +12.5% |
| Q2 2021 | $325,000 | – | 2,253 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 498,558 | $31,294,000 | 31.24% |
| NEA Management Company, LLC | 1,590,002 | $365,593,000 | 10.56% |
| Ariose Capital Management Ltd | 37,900 | $2,379,000 | 9.30% |
| ARK Investment Management | 9,404,071 | $590,294,000 | 2.46% |
| NIA IMPACT ADVISORS, LLC | 80,082 | $5,027,000 | 2.44% |
| Nikko Asset Management Americas, Inc. | 4,619,747 | $291,044,000 | 2.14% |
| PLUSTICK MANAGEMENT LLC | 50,000 | $3,139,000 | 1.98% |
| Integral Health Asset Management, LLC | 120,000 | $7,532,000 | 1.96% |
| Valiant Capital Management, L.P. | 240,683 | $15,108,000 | 1.73% |
| Deuterium Capital Management, LLC | 18,000 | $1,130,000 | 1.45% |